You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Immune monitoring in patients with colorectal cancer stage II
  1. Eva Zavadova1,
  2. Michal Vocka1,
  3. Jan Spacek1,
  4. Nicole Francis2,
  5. Bohuslav Konopasek1,
  6. Terezie Fucikova3,
  7. Helena Skalova4,
  8. Pavel Dundr4,
  9. Lubos Petruzelka1,
  10. Tilman T Rau5,
  11. Carol Geppert5 and
  12. Arndt Hartmann5
  1. Aff1 grid.411798.20000000091009940Department of OncologyGeneral Teaching Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic
  2. Aff2 grid.4491.8000000041937116X1st Faculty of Medicine Charles University Prague Czech Republic
  3. Aff3 grid.411798.20000000091009940Institute of immunology and microbiologyGeneral Teaching Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic
  4. Aff4 grid.411798.20000000091009940Dept. of pathologyGeneral Teaching Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic
  5. Aff5 grid.5330.50000000121073311Institute of PathologyUniversity Erlangen-Nürnberg Erlangen Germany

https://doi.org/10.1186/2051-1426-3-S2-P266

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Immunoscore has been shown to be a very powerful prognositc indicator in patients with clinically localized colorectal cancer, with no detectable tumour spread to lymph nodes or distant organs. These patients are usually treated with surgical removal of the tumour only. However, approximately 25% of these patients will have recurrence of their disease. No tumour-associated marker to predict the recurrence of this subgroup of patients and define who could benefit from adjuvant therapy is used in clinical routine[1] In addition to immunoscore, other parameters of the immune response are investigated – mostly cellular immunity and the production of immunosuppressive and neoangiogenic markers. Vascular endothelial growth factor (VEGF) is the factor responsible for neoangiogenesis and it is being considered as a possible prognostic marker of disease progression. Transforming growth factor-beta (TGF-beta) is also neoangiogenic and a highly immunosuppressive factor as it suppresses the body's natural immunity against tumours and is also being considered as another possible prognostic marker of disease progression.

    Aim

    To monitor the immune response in patients with stage II colorectal cancer, with a focus on cellular as well as humoral immunity. TGF-beta and VEGF levels were followed.

    Methods

    38 patients with stage II colon cancer included in the research project received routine cancer treatment. . Basic parameters – histological type and grade, proliferative markers – were established at baseline. Patients were evaluated by a clinical immunooncologist to exclude any immune disorders of allergic or autoimmune origin. TGF-beta and VEGF were measured using ELISA, and anti-tumour cellular immunity (CD4, CD8, T-reg, B cells) were measured via flow cytometry.

    Results

    In patients with stage II colorectal cancer, predominantly a depression in cellular immunity was seen. Plasma levels of immunglobulins were also reduced, particularly the IgG3 subtype. Most patients showed some clinical symptoms of immunodeficiency, such as frequent respiratory tract infections and/or herpetic infections. TGF-beta and VEGF plasma levels were increased.

    Conclusion

    The correlation of these neoangiogenic and immunosuppressive factors, as well as the state of anticancer immunity, could help in the future as a prognostic marker and contribute to the selection of targeted adjuvant as well as immune therapy in patients with colorectal cancer stage II.

    Dedication

    This project was supported by grant of Czech Ministery of Health, 15-28188A, League against cancer and PRVOUK.

    References

    1. 1.↵
      1. Galon J, et al
      . Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. Journal of Pathology. 2014;232:2199–209. pmcid:4255306 doi:10.1002/path.4287
      OpenUrlCrossRefPubMedWeb of Science